BIO Comments on FDA Draft Guidance on Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease
February 15, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease.
BIO welcomes the FDA’s efforts to provide clear, concise guidance on the regulatory and scientific framework for product developers of targeted treatments. This will help sponsors with clinical trial development, including the types/levels of evidence to support a grouping strategy for clinical trial eligibility and benefit-risk evaluation approaches within a disease exhibiting differences in molecular subset.
BIO encourages the FDA to continue to gather stakeholder input on the development of targeted therapies to ensure the guidance keeps pace with scientific advances. BIO’s comments include additional suggestions to clarify the guidance, the scope, and FDA’s receptivity to innovative approaches for the development of targeted therapies.
Download Full Comments Below
BIO Letter Low-Frequency Molecular Subsets FINAL 2-15-18
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
In response to their advance notice of proposed rulemaking (ANPRM), BIO submitted comments to the DOJ's National Security Division on implementing the White House Executive Order of February 28, 2024, “Preventing Access to Americans’ Bulk Sensitive…
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease.
BIO welcomes the FDA’s efforts to provide clear, concise guidance on the regulatory and scientific framework for product developers of targeted treatments. This will help sponsors with clinical trial development, including the types/levels of evidence to support a grouping strategy for clinical trial eligibility and benefit-risk evaluation approaches within a disease exhibiting differences in molecular subset.
BIO encourages the FDA to continue to gather stakeholder input on the development of targeted therapies to ensure the guidance keeps pace with scientific advances. BIO’s comments include additional suggestions to clarify the guidance, the scope, and FDA’s receptivity to innovative approaches for the development of targeted therapies.